KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

CRISPR Therapeutics AG (CRSP) Consolidated Net Income (2016 - 2025)

Historic Consolidated Net Income for CRISPR Therapeutics AG (CRSP) over the last 11 years, with Q4 2025 value amounting to -$163.1 million.

  • CRISPR Therapeutics AG's Consolidated Net Income fell 10646.97% to -$163.1 million in Q4 2025 from the same period last year, while for Dec 2025 it was -$614.1 million, marking a year-over-year decrease of 5052.6%. This contributed to the annual value of -$614.1 million for FY2025, which is 5053.29% down from last year.
  • Latest data reveals that CRISPR Therapeutics AG reported Consolidated Net Income of -$163.1 million as of Q4 2025, which was down 10646.97% from -$106.4 million recorded in Q3 2025.
  • CRISPR Therapeutics AG's Consolidated Net Income's 5-year high stood at $759.2 million during Q2 2021, with a 5-year trough of -$208.6 million in Q2 2025.
  • Its 5-year average for Consolidated Net Income is -$74.1 million, with a median of -$114.9 million in 2021.
  • In the last 5 years, CRISPR Therapeutics AG's Consolidated Net Income soared by 105287.85% in 2021 and then tumbled by 23481.09% in 2024.
  • Over the past 5 years, CRISPR Therapeutics AG's Consolidated Net Income (Quarter) stood at -$141.2 million in 2021, then rose by 20.1% to -$112.9 million in 2022, then skyrocketed by 151.93% to $58.6 million in 2023, then tumbled by 234.81% to -$79.0 million in 2024, then tumbled by 106.47% to -$163.1 million in 2025.
  • Its Consolidated Net Income was -$163.1 million in Q4 2025, compared to -$106.4 million in Q3 2025 and -$208.6 million in Q2 2025.